Oral Semaglutide – A Phase 3 Trial in Patients with Type 2 Diabetes
Sep 24, 2019
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy
On September 20, 2019, The U.S. Food and Drug Administration approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise. The results of this phase 3 trial give more background on the safety and efficacy of this groundbreaking drug....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.